Clorox

Primary moat drivers are intangible assets and scale. The portfolio includes iconic names like the flagship bleach/disinfecting franchise, Glad, Kingsford, Hidden Valley, Brita and Burt’s Bees.

Management discloses that about 80 percent of sales come from brands with #1 or #2 category share, which, coupled with entrenched retailer relationships and marketing, sustains shelf space and slows share loss to private label. We see moderate cost advantages in procurement and manufacturing from scale and category expertise.

Switching costs for consumers are low, and there is no network effect. Efficient scale is present in certain mid‑sized categories (trash bags, charcoal, cat litter) where category economics and shelf constraints dissuade fragmented entry, but pricing gaps can spur private label trade‑down in downturns.

We also note vulnerability to commodity inputs and retailer mix. Segment definitions and product lists in filings confirm breadth across Health and Wellness, Household, Lifestyle, and International. Overall, we weight intangible assets and scale heavily, yielding a solid but not unassailable moat.

The business has demonstrated ability to take pricing and restore margins following the inflation shock. FY2025 gross margin reached 45.2 percent, up 220 basis points year over year on cost savings and mix. The company plans continued brand support at roughly 11 percent of net sales to reinforce willingness to pay.

That said, categories like bags/wraps, litter and dressings face private-label pressure, limiting infinite pricing. The Q1 FY2026 gross margin dip to 41.7 percent was tied to ERP-related volume deleverage and manufacturing/logistics costs, not structural loss of pricing.

Net, we view realized pricing and productivity as sufficient to defend mid‑40s gross margin, with ongoing elasticity risk in more commoditized lines.

Household and cleaning categories are everyday needs with recurring, recession‑resistant demand and multi‑channel distribution. Revenue volatility in 2023 stemmed from a cyberattack; by FY2025 operations normalized and the company reported stable sales and strong cash flow.

FY2026 is temporarily affected by ERP shipment timing and increased advertising, but management reaffirmed the outlook and indicated the majority of the rollout is complete. The portfolio is largely U.S.-centric, reducing geopolitical risk, and the company has exited the more volatile Better Health VMS and Argentina businesses, simplifying the mix.

We do note periodic recall and quality risks (e.g., the 2022 Pine‑Sol recall) and retailer inventory dynamics can create quarter‑to‑quarter noise, but the long‑term demand curve remains steady.

As of September 30, 2025, cash and cash equivalents were 166 million, notes and loans payable 218 million and long‑term debt 2.485 billion. Interest coverage is robust (FY2025 EBIT around 1.16 billion vs 88 million interest expense) and credit ratings remain investment grade (S&P BBB+, Moody’s Baa1).

The company has a 1.2 billion revolver maturing 2030. Known upcoming cash use is the January 2026 purchase of P&G’s 20 percent Glad stake, shown in material cash requirements at 476 million. We estimate TTM FCF of ~636 million through Q1 FY2026, implying net debt at roughly 4x FCF, acceptable for a stable staple with strong visibility.

The 2023 cyberattack has transitioned from a liquidity risk to resolved operations and insurance recoveries in FY2025. Overall, the balance sheet is sound with adequate flexibility to fund ERP and the Glad obligation while maintaining the dividend.

Capital deployment has prioritized organic investment, digital transformation, and dividends, with targeted portfolio moves. FY2025 capex was 220 million (~3.1 percent of sales) as the company invests in ERP and productivity.

The multi‑year digital program (570 to 580 million, roughly 75 percent expensed and about 70 percent ERP-related) should yield long‑term efficiencies. Management divested the Better Health VMS business and previously exited Argentina to streamline focus.

Share repurchases resumed in FY2025 after several years of pause, and the company maintained its multi‑decade dividend growth streak, raising the quarterly dividend to 1.24. On the cautious side, the VMS acquisition several years ago ultimately proved noncore and the 2026 Glad buyout is a sizable cash call.

Overall, allocation is improving and disciplined, with an emphasis on returns and simplification.

Leadership executed through a complex operational recovery, restored margins, and is driving a multi‑year digital and productivity agenda. Chair and CEO Linda Rendle continues to emphasize brand investment and cost savings while simplifying the portfolio.

The CFO transition in April 2025 to long‑time insider Luc Bellet supports continuity in financial discipline and the transformation program. Communication on ERP timing effects and FY2026 outlook has been transparent. We assign a solid rating for steady execution and credible long‑term targets, with positive succession planning and governance.